Contribution of p53 to metastasis

Cancer Discovery

Volumn 4, Issue 4, 2014, Pages 405-414

  Powell, Emily ^a   Piwnica Worms, David ^a   Piwnica Worms, Helen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANOIKIS; APOPTOSIS; BREAST CANCER; CELL INVASION; CELL MIGRATION; CELL MOTILITY; DIFFERENTIATION; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; GENOME; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NEOPLASM; NONHUMAN; PHENOTYPE; REVIEW; SENESCENCE; SURVIVAL; TUMOR GROWTH; BREAST TUMOR; CELL COMMUNICATION; FEMALE; GENETICS; METABOLISM; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL COMMUNICATION; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897941730     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0136     Document Type: Review

References (80)

1. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110.
2. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-13.
3. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124: 207-19.
4. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006; 6: 276.
5. Muller PA, Vousden KH, Norman JC. P53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209-18.
6. Xia M, Land H. Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nat Struct Mol Biol 2007; 14: 215-23.
7. Mashimo T, Watabe M, Hirota S, Hosobe S, Miura K, Tegtmeyer PJ, et al. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p 53. Proc Natl Acad Sci U S A 1998; 95: 11307-1311.
8. Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett 2006; 240: 183-94.
9. Zhang XA, He B, Zhou B, Liu L. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003; 278: 27319-28.
10. Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, et al. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol 2005; 18: 1289-94.
11. Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci 2010; 15: 901-12.
12. Tanikawa C, Furukawa Y, Yoshida N, Arakawa H, Nakamura Y, Matsuda K. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway. Oncogene 2009; 28: 3081-92.
13. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012; 22: 396-403.
14. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. P53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 1467.
15. Meyer KM, Hess SM, Tlsty TD, Leadon SA. Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 1999; 18: 5795-805.
16. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, et al. Mir-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256-7421.
17. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, et al. P53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 2009; 11: 694-704.
18. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999; 13: 2207-2217.
19. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134: 62-73.
20. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, et al. P53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005; 7: 165-171.
21. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J. P53 suppresses the self-renewal of adult neural stem cells. Development 2006; 133: 363-369.
22. Nieto MA, Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 2012; 22: 361-368.
23. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
24. Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995; 23: 3710-3107.
25. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, et al. P53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000; 275: 6051-6054.
26. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D, et al. Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 2001; 61: 6945-51.
27. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
28. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997; 17: 6330-6338.
29. Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. P53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem 1999; 274: 11535-11540.
30. Sakuma S, Saya H, Tada M, Nakao M, Fujiwara T, Roth JA, et al. Receptor protein tyrosine kinase DDR is up-regulated by p53 protein. FEBS Lett 1996; 398: 165-169.
31. Brummer O, Athar S, Riethdorf L, Loning T, Herbst H. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 1999; 435: 566-73.
32. Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, et al. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 1998; 77: 926-31.
33. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276: 43503-8.
34. Ozdemir E, Kakehi Y, Okuno H, Habuchi T, Okada Y, Yoshida O. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. J Urol 1997; 158: 206-11.
35. Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, et al. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res 2006; 4: 803-10.
36. Iotsova V, Stehelin D. Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth Differ 1996; 7: 629-34.
37. Mukhopadhyay UK, Eves R, Jia L, Mooney P, Mak AS. p53 suppresses Src-induced podosome and rosette formation and cellular invasiveness through the upregulation of caldesmon. Mol Cell Biol 2009; 29: 3088-98.
38. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-26.
39. Fidler IJ, Nicolson GL. Fate of recirculating B16 melanoma metastatic variant cells in parabiotic syngeneic recipients. J Natl Cancer Inst 1977; 58: 1867-72.
40. Liotta LA, Vembu D, Saini RK, Boone C. In vivo monitoring of the death rate of artificial murine pulmonary micrometastases. Cancer Res 1978; 38: 1231-6.
41. Varani J, Lovett EJ, Elgebaly S, Lundy J, Ward PA. In vitro and in vivo adherence of tumor cell variants correlated with tumor formation. Am J Pathol 1980; 101: 345-352.
42. Vitale M, Di Matola T, Bifulco M, Casamassima A, Fenzi G, Rossi G. Apoptosis induced by denied adhesion to extracellular matrix (anoikis) in thyroid epithelial cells is p53 dependent but fails to correlate with modulation of p53 expression. FEBS Lett 1999; 462: 57-60.
43. Nikiforov MA, Hagen K, Ossovskaya VS, Connor TM, Lowe SW, Deichman GI, et al. p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 1996; 13: 1709-1719.
44. Zhong X, Rescorla FJ. Cell surface adhesion molecules and adhesioninitiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal 2012; 24: 393-401.
45. Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, et al. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2009; 2: ra35.
46. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999; 55: 48-63.
47. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li- Fraumeni syndrome. Cell 2004; 119: 861-872.
48. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
49. Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007; 26: 2177-2184.
50. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, et al. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 2001; 20: 4163-4172.
51. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004; 64: 8318-8327.
52. Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 2006; 25: 359-369.
53. Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, et al. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol 2009; 385: 249-65.
54. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87-98.
55. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1241.
56. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway, Cell 2012; 148: 244-58
57. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone, Cancer Cell 2003; 3: 537-49
58. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-24.
59. Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG, Proteomic identification of the wt-p53-regulated tumor cell secretome, Oncogene 2006; 25: 7650-61
60. Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ Jr, Broxmeyer HE, Kopelovich L, et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion, Oncogene 2007; 26: 3329-37
61. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S, Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years, J Clin Oncol 1989; 7: 1239-51
62. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours, Nature 2012; 490: 61-70
63. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM, Molecular characterization of Basal-like and non-basal-like triplenegative breast cancer, Oncologist 2013; 18: 123-33
64. Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, et al. p53 in breast cancer subtypes and new insights into response to chemotherapy, Breast 2013; 222-279
65. Evans SC, Lozano G, The Li-Fraumeni syndrome: an inherited susceptibility to cancer, Mol Med Today 1997; 3: 390-5
66. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D, P53 expression in breast cancer, Int J Cancer 1988; 41: 178-83
67. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft, Nature 2010; 464: 999-1005
68. Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V, p53 mutations in matched primary and metastatic human tumors, Mol Carcinog 1995; 13: 166-72
69. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression, Nature 2010; 468: 572-5
70. Martins CP, Brown-Swigart L, Evan GI, Modeling the therapeutic efficacy of p53 restoration in tumors, Cell 2006; 127: 1323-34
71. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo, Nature 2007; 445: 661-5
72. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature 2007; 445: 656-60
73. Secchiero P, Bosco R, Celeghini C, Zauli G, Recent advances in the therapeutic perspectives of Nutlin-3, Curr Pharm Des 2011; 17: 569-77
74. Parker LP, Wolf JK, Price JE, Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines, Ann Clin Lab Sci 2000; 30: 395-405
75. Yu X, Vazquez A, Levine AJ, Carpizo DR, Allele-specific p53 mutant reactivation, Cancer Cell 2012; 21: 614-25
76. Selivanova G, Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 2010; 20: 46-56
77. Hermeking H, MicroRNAs in the p53 network: micromanagement of tumour suppression, Nat Rev Cancer 2012; 12: 613-26
78. Golubovskaya VM, Finch R, Kweh F, Massoll NA, Campbell-Thompson M, Wallace MR, et al. P53 regulates FAK expression in human tumor cells, Mol Carcinog 2008; 47: 373-82
79. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice, J Clin Invest 2011; 121: 3343-56
80. Dameron KM, Volpert OV, Tainsky MA, Bouck N, The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin, Cold Spring Harb Symp Quant Biol 1994; 59: 483-9